Reports Q3 revenue $58.4M, consensus $53.18M. “I’m extremely proud of the entire PROCEPT team for their collective effort and execution in launching HYDROS in the third quarter,” said Reza Zadno, Chief Executive Officer. “After receiving HYDROS FDA clearance in August, we successfully converted the third quarter capital pipeline, manufactured sufficient quantities of commercial product, trained our clinical teams while mitigating downside pressure on procedures, and effectively managed customer relationships during this critical phase of our Company’s growth. As a result, we delivered another successful quarter with annual revenue growth of 66% and record gross margins of 63.2%.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Is PRCT a Buy, Before Earnings?
- Closing Bell Movers: DocuSign up over 5% after entering S&P MidCap 400
- Procept BioRobotics announces FDA approval to initiate Aquablation therapy study
- Procept BioRobotics price target raised to $99 from $75 at TD Cowen
- BTIG medical technology analyst holds an analyst/industry conference call